Literature DB >> 9882449

Heparin binding and augmentation of C1 inhibitor activity.

E E Caldwell1, A M Andreasen, M A Blietz, J N Serrahn, V VanderNoot, Y Park, G Yu, R J Linhardt, J M Weiler.   

Abstract

Heparin and other glycosaminoglycans have profound activity in vitro on the regulation of complement activity. The studies reported here examined the mechanism whereby heparin enhances C1 esterase inhibitor (C1INH) activity on C1 esterase (C1). The interaction of heparin and heparan sulfate with C1INH was first examined using surface plasmon resonance. Heparin was immobilized on a biosensor chip in two orientations, at its reducing end and in midchain, and heparan sulfate was immobilized at its reducing end. Heparin immobilized at its reducing end interacted with C1INH, giving an association constant (Ka) value of 1.43 x 10(7) M-1, whereas heparin immobilized in midchain afforded a Ka value of 7 x 10(6) M-1. No interaction between C1INH and heparan sulfate could be observed. Next, the augmentation of C1INH by heparin (Mr (av) 13,000), low-molecular-weight (LMW) heparin (Mr (av) 5000), and heparan sulfate (Mr (av) 11,000) was determined. C1INH alone was at least 10, 000 times more active in inhibiting fluid phase C1 compared with erythrocyte-bound C1 (EAC1). When C1 was in the fluid phase, both heparin and LMW heparin were relatively ineffective at augmenting C1INH activity on C1. In contrast, when C1 was present as EAC1, heparin augmented C1INH activity at all C1INH concentrations examined and LMW heparin was up to 1.3 times more effective than heparin. This augmentation only occurred when both C1INH and heparin were present together with the EAC1. Hence, although surface plasmon resonance shows that heparin binds to C1INH, heparin augmentation of C1INH activity appears to require a terniary complex in which cell bound C1 interacts with both heparin and C1INH. This is the first report of LMW heparin augmenting C1INH activity. Heparan sulfate neither interacted with C1INH nor did it augment C1INH activity. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882449     DOI: 10.1006/abbi.1998.0996

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  11 in total

1.  Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation.

Authors:  Juan S Danobeitia; Tiffany J Zens; Peter J Chlebeck; Laura J Zitur; Jose A Reyes; Michael J Eerhart; Jennifer Coonen; Saverio Capuano; Anthony M D'Alessandro; Jose R Torrealba; Daniel Burguete; Kevin Brunner; Edwin Van Amersfoort; Yolanda Ponstein; Cees Van Kooten; Ewa Jankowska-Gan; William Burlingham; Jeremy Sullivan; Arjang Djamali; Myron Pozniak; Yucel Yankol; Luis A Fernandez
Journal:  Am J Transplant       Date:  2020-02-20       Impact factor: 8.086

2.  Preparation and isolation of neoglycoconjugates using biotin-streptavidin complexes.

Authors:  B Kuberan; N S Gunay; J S Dordick; R J Linhardt
Journal:  Glycoconj J       Date:  1999-06       Impact factor: 2.916

3.  Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver.

Authors:  L Bergamaschini; G Gobbo; S Gatti; L Caccamo; P Prato; M Maggioni; P Braidotti; R Di Stefano; L R Fassati
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

4.  Metabolic alteration of the N-glycan structure of a protein from patients with a heterozygous protein deficiency.

Authors:  Fuming Zhang; Andrew D Bries; Sybil C Lang; Qun Wang; David W Murhammer; John M Weiler; Robert J Linhardt
Journal:  Biochim Biophys Acta       Date:  2004-12-24

5.  Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance.

Authors:  Haining Yu; Eva M Muñoz; R Erik Edens; Robert J Linhardt
Journal:  Biochim Biophys Acta       Date:  2005-08-15

6.  Complement Blockade in Recipients Prevents Delayed Graft Function and Delays Antibody-mediated Rejection in a Nonhuman Primate Model of Kidney Transplantation.

Authors:  Michael J Eerhart; Jose A Reyes; Casi L Blanton; Juan S Danobeitia; Peter J Chlebeck; Laura J Zitur; Megan Springer; Erzsebet Polyak; Jennifer Coonen; Saverio Capuano; Anthony M D'Alessandro; Jose Torrealba; Edwin van Amersfoort; Yolanda Ponstein; Cees van Kooten; William Burlingham; Jeremy Sullivan; Myron Pozniak; Weixiong Zhong; Yucel Yankol; Luis A Fernandez
Journal:  Transplantation       Date:  2022-01-01       Impact factor: 5.385

7.  Profiling heparin-chemokine interactions using synthetic tools.

Authors:  Jose L de Paz; E Ashley Moseman; Christian Noti; Laura Polito; Ulrich H von Andrian; Peter H Seeberger
Journal:  ACS Chem Biol       Date:  2007-11-20       Impact factor: 5.100

8.  Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7.

Authors:  Wyndham W Lathem; Tessa Bergsbaken; Rodney A Welch
Journal:  J Exp Med       Date:  2004-04-19       Impact factor: 14.307

9.  Regulation of Complement and Contact System Activation via C1 Inhibitor Potentiation and Factor XIIa Activity Modulation by Sulfated Glycans - Structure-Activity Relationships.

Authors:  Ann-Kathrin Schoenfeld; Eric Lahrsen; Susanne Alban
Journal:  PLoS One       Date:  2016-10-26       Impact factor: 3.240

10.  Exopolysaccharides isolated from hydrothermal vent bacteria can modulate the complement system.

Authors:  Anthony Courtois; Christian Berthou; Jean Guézennec; Claire Boisset; Anne Bordron
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.